Program
clifutinib
Also written as “Clifutinib Besylate”, “Clifutinib” and “[14C]Clifutinib”.
Its studies are mostly in Leukemia, Myeloid, Acute, led by Sunshine Lake Pharma.
Furthest: phase 3, since Oct 14, 20225 company-led studies, 3 open or runningNext primary completion: Apr 23, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sunshine Lake Pharma | 53 open or running | phase 3since Oct 14, 2022 | Mar 22, 2021 | Apr 23, 2027phase 1 · NCT07341672 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 22, 2021First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT04827069 · 75 enrolled · China
- Nov 12, 2021Phase 2 study in Leukemia, Myeloid, AcuteNCT05133882 · 133 planned · China
- Oct 14, 2022Phase 3 study in Leukemia, Myeloid, AcuteNCT05586074 · 324 planned · China
- Sep 22, 2025Phase 1 study in Healthy Adult MaleNCT07211165 · 6 enrolled · China
- Dec 23, 2025Phase 1 study in Healthy Adult SubjectNCT07341672 · 80 planned · China
Ahead
- Apr 23, 2027Primary completion: phase 1 study in Healthy Adult SubjectNCT07341672
- Nov 30, 2027Primary completion: phase 3 study in Leukemia, Myeloid, AcuteNCT05586074
- Dec 31, 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT05133882
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07341672Healthy Adult Subject · China | 1 | Not yet recruiting | Apr 23, 2027 | 80 |
| NCT07211165Healthy Adult Male · China | 1 | Completed | Nov 5, 2025 | 6 |
| NCT05586074Leukemia, Myeloid, Acute · China | 3 | Recruiting | Nov 30, 2027 | 324 |
| NCT05133882Leukemia, Myeloid, Acute · China | 2 | Recruiting | Dec 31, 2027 | 133 |
| NCT04827069Leukemia, Myeloid, Acute · China | 1 | Completed | Aug 21, 2023 | 75 |
How it is read
Names in the registry
- “Clifutinib Besylate”, 2 entries
- “Clifutinib”, 2 entries
- “[14C]Clifutinib”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.